CERS Q1 2026 Earnings Call Summary

Cerus Corporation (CERS) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Product Revenue: $53.7 million, a 24% increase year-over-year.
Total Revenue: Increased by 23% compared to Q1 2025, driven by both product and government contract revenue.
Gross Margin: 52%, down from 58.8% in Q1 2025, attributed to inflationary pressures and foreign currency impacts.
Operating Expenses: Decreased by 7% year-over-year, with SG&A expenses stable and R&D expenses lower due to reduced development costs.
Net Loss: $1.6 million, showing year-over-year improvement.
Non-GAAP Adjusted EBITDA: $4 million, marking the eighth consecutive quarter of positive adjusted EBITDA.
Cash and Equivalents: $80.4 million at the end of Q1 2026, down from $82.9 million at the end of 2025.

2. Strategic Updates and Business Highlights

Core Priorities: Focus on sustainable double-digit growth, advancing innovation, and strengthening financial foundation.
U.S. Platelet Franchise: Strong performance with a 6% increase in platelet volumes and a 9% increase in treatable doses compared to Q1 2025.
International Growth: EMEA business performed well, particularly in France and Belgium, supported by a multiyear contract with the French Blood Establishment.
Group Purchasing Agreement: Early signs of traction from the agreement with Blood Centers of America, which is expected to enhance market penetration.
Innovation: Successful rollout of the INT-200 illuminator and plans for PMA submission for the INT-100 device to the U.S. FDA.

3. Forward Guidance and Outlook

Revised Product Revenue Guidance: Increased to $227 million to $231 million for 2026, reflecting 10% to 12% growth year-over-year.
IFC Revenue Guidance: Raised to $22 million to $24 million, indicating approximately 30% to 40% growth.
Long-Term Growth Prospects: Confidence in continued growth in both U.S. and international markets, with a focus on expanding adoption of INTERCEPT technology.

4. Bad News, Challenges, or Points of Concern

Gross Margin Pressure: Expected to remain in the low 50s range due to ongoing inflationary pressures, tariffs, and foreign currency impacts.
Logistical Challenges: Ongoing conflict in the Middle East may affect shipment timing, although management believes potential disruptions can be mitigated.
Market Penetration: While growth is strong, the company still holds a single-digit market share in the U.S. for IFC, indicating room for improvement.

5. Notable Q&A Insights

Market Dynamics: The strength in the U.S. INTERCEPT platelet franchise is expected to continue, supported by the BCA agreement.
IFC Growth: Transitioning to kit-based sales is anticipated to enhance operational efficiency and market penetration.
Regulatory Milestones: The CE Mark for red blood cells is expected in the first half of 2027, with the Phase III RedeS study readout anticipated in Q4 2026.
China Market: The company remains committed to pursuing regulatory approval for platelets in China, with expectations for revenue generation towards the latter part of the decade.

Overall, Cerus Corporation reported a strong start to 2026, with significant revenue growth and positive operational metrics, while also facing challenges related to gross margins and market penetration. The leadership transition to Vivek Jayaraman is expected to continue the company's focus on innovation and growth.

CERS — Cerus Corporation